Conferoport 1 mg, harde capsules met verlengde afgifte

国家: 荷兰

语言: 荷兰文

来源: CBG-MEB (College ter Beoordeling van Geneesmiddelen)

有效成分:

TACROLIMUS 1-WATER 1,022 mg/stuk SAMENSTELLING overeenkomend met ; TACROLIMUS 0-WATER 1 mg/stuk

可用日期:

Sandoz B.V. Veluwezoom 22 1327 AH ALMERE

ATC代码:

L04AD02

INN（国际名称）:

TACROLIMUS 1-WATER 1,022 mg/stuk SAMENSTELLING overeenkomend met ; TACROLIMUS 0-WATER 1 mg/stuk

药物剂型:

Capsule met verlengde afgifte, hard

组成:

ALLURAROOD AC (E 129) ; ALLURAROOD AC ALUMINIUM LAK (E 129) ; BRILJANTBLAUW FCF (E 133) ; BRILJANTBLAUW FCF ALUMINIUMLAK (E133) ; ETHYLCELLULOSE (E 462) ; GELATINE (E 441) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; LACTOSE 1-WATER ; LECITHINE, SOYA (E 322) ; MAGNESIUMSTEARAAT (E 470b) ; PROPYLEENGLYCOL (E 1520) ; SCHELLAK GLAZE, GEDEELTELIJK VERESTERD ; SIMETICON ; TITAANDIOXIDE (E 171) ; ZONNEGEEL FCF (E 110) ; ZONNEGEEL FCF ALUMINIUMLAK (E 110) ; ZWARTE INKT, ALLURAROOD AC (E129) ; ALLURAROOD AC ALUMINIUM LAK (E 129) ; BRILJANTBLAUW FCF (E 133) ; BRILJANTBLAUW FCF ALUMINIUMLAK (E133) ; ETHYLCELLULOSE (E 462) ; GELATINE (E 441) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; LACTOSE 1-WATER ; LECITHINE, SOYA (E 322) ; MAGNESIUMSTEARAAT (E 470b) ; PROPYLEENGLYCOL (E 1520) ; SCHELLAK GLAZE, GEDEELTELIJK VERESTERD ; SIMETICON ; TITAANDIOXIDE (E 171) ; ZONNEGEEL FCF (E 110) ; ZONNEGEEL FCF ALUMINIUMLAK (E 110) ; ZWARTE INKT

给药途径:

Oraal gebruik

治疗领域:

Tacrolimus

授权日期:

1900-01-01

资料单张

Sandoz B.V.
Page 1/
13
Conferoport 0,5/1/2/3/5 mg, harde capsules met verlengde afgifte
RVG 124871-73-74-75-76
1313-v7
1.3.1.3 Bijsluiter
November 2023
PACKAGE LEAFLET
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
Conferoport 0,5 mg, harde capsules met verlengde afgifte
Conferoport 1 mg, harde capsules met verlengde afgifte
Conferoport 2 mg, harde capsules met verlengde afgifte
Conferoport 3 mg, harde capsules met verlengde afgifte
Conferoport 5 mg, harde capsules met verlengde afgifte
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What [Nationally completed name] is and what it is used for
2. What you need to know before you take [Nationally completed name]
3. How to take [Nationally completed name]
4. Possible side effects
5. How to store [Nationally completed name]
6. Contents of the pack and other information
1. WHAT [NATIONALLY COMPLETED NAME] IS AND WHAT IT IS USED FOR
[Nationally completed name] contains the active substance tacrolimus.
It is an immunosuppressant.
Following your organ transplant (liver, kidney), your body’s immune
system will try to reject the new
organ. [Nationally completed name] is used to control your body’s
immune response, enabling your
body to accept the transplanted organ.
You may also be given [Nationally completed name] for an ongoing
rejection of your transplanted
liver, kidney, heart or other organ when any previous treatment you
were taking was unable to control
this immune response after your transplantation.
[Nationally completed name] is used in adults.
San

产品特点

Sandoz B.V.
Page 1/25
Conferoport 0,5/1/2/3/5 mg, harde capsules met verlengde
afgifte
RVG 124871-73-74-75-76
1313-v6
1.3.1.1 SPC
Mei 2022
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
Conferoport 0,5 mg, harde capsules met verlengde afgifte
Conferoport 1 mg, harde capsules met verlengde afgifte
Conferoport 2 mg, harde capsules met verlengde afgifte
Conferoport 3 mg, harde capsules met verlengde afgifte
Conferoport 5 mg, harde capsules met verlengde afgifte
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prolonged-release hard capsule contains 0.5 mg of tacrolimus (as
monohydrate).
Excipient(s) with known effect
Each prolonged-release hard capsule contains 51 mg of lactose (as
monohydrate).
Each prolonged-release hard capsule contains 5.4 microgram of Sunset
yellow FCF (E 110).
Each prolonged-release hard capsule contains 0.4 microgram of Allura
red AC (E 129).
Each prolonged-release hard capsule contains 3.4 microgram of
tartrazine (E 102).
Each prolonged-release hard capsule contains 1 mg of tacrolimus (as
monohydrate).
Excipient(s) with known effect
Each prolonged-release hard capsule contains 102 mg of lactose (as
monohydrate).
Each prolonged-release hard capsule contains 7.4 microgram of Sunset
yellow FCF (E 110).
Each prolonged-release hard capsule contains 0.6 microgram of Allura
red AC (E 129).
Each prolonged-release hard capsule contains 2 mg of tacrolimus (as
monohydrate).
Excipient(s) with known effect
Each prolonged-release hard capsule contains 204 mg of lactose (as
monohydrate).
Each prolonged-release hard capsule contains 9.3 microgram of Sunset
yellow FCF (E 110).
Each prolonged-release hard capsule contains 0.8 microgram of Allura
red AC (E 129).
Each prolonged-release hard capsule contains 17.4 microgram of
tartrazine (E 102).
Each prolonged-release hard capsule contains 3 mg of tacrolimus (as
monohydrate).
Sandoz B.V.
Page 2/25
Conferoport 0,5/1/2/3/5 mg, harde capsules met verlengde
afgifte
RVG 124871-73-74-75-76
1313-v6
1.3.1.1 SPC
Mei 2022
Excipient(s) with known effec